Drug Approval | November 23, 2025
FDA approves combo therapy for Cisplatin-ineligible muscle-invasive bladder cancer patients
The approvals target adult MIBC patients who are ineligible for cisplatin-based chemotherapy
The approvals target adult MIBC patients who are ineligible for cisplatin-based chemotherapy
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
The formulation is backed by over 80 clinical trials and 200 scientific publications
False positive rates?ranged from 0% to 41%, meaning some labs incorrectly identified bacteria that weren’t present in the sample
LANXESS will highlight its commitment to combatting antimicrobial resistance by presenting science-based disinfection solutions
The new MimixTM GeniTM reference standards were developed from the extensively tested Genome-in-a-Bottle Consortium (GIAB) cell line
Glenmark will begin distribution in November 2025
From material selection to cooling tower management, every small decision affects long-term equipment reliability
This is the first industry-academia collaboration in the country, initiated through the CSR route, for advancing research in the areas of immuno-therapeutics and regenerative medicines
The FW500 is designed to meet the evolving needs of mid-sized diagnostic laboratories
Subscribe To Our Newsletter & Stay Updated
